Navigation Links
BioMarin Announces Third Quarter 2008 Financial Results
Date:10/28/2008

,907 $47,982

Current portion of acquisition obligation,

net of discount 6,309 71,158

Deferred revenue 5,327 1,443

Other current liabilities - 152

Total current liabilities 61,543 120,735

Convertible debt 497,375 497,240

Long-term portion of acquisition obligation,

net of discount 66,553 -

Other long-term liabilities 2,082 3,162

Total liabilities 627,553 621,137

Stockholders' equity:

Common stock, $0.001 par value: 250,000,000

shares authorized at December 31, 2007 and

September 30, 2008; 97,114,159 and 99,691,581

shares issued and outstanding at December 31,

2007 and September 30, 2008, respectively 97 100

Additional paid-in capital 794,917 841,657

Company common stock held by deferred

compensation plan - (939)

Accumulated other comprehensive income (loss) 139 (1,818)

Accumulated deficit (607,427) (601,102)

Total stockholders' equity 187,726 237,901

Total liabilities and stockholders' equity $815,279 $859,038

(1) December 31, 2007 balances were derived from the audited consolidated

financials.

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three and Nine Months Ended September 30, 2007 and 2008

(In thousands, except for per share data, unaudited)

Three Mon
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioMarin Corrects Information Included in Bloomberg Article
2. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Citi Biotech Day
5. BioMarin Announces Roll-Out of National PKU Registry
6. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Collins Stewart Growth Conference
8. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
9. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
10. BioMarin to Host Research and Development Day June 5th
11. BioMarin to Present at the Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... a Medicare Part D provider, with offices in New ... the company and ProCare, its former pharmacy benefit manager, ... ProCare based on Fox,s allegations of negligence and breach ... of Fox Insurance Company commented: "Fox Insurance is gratified ...
... Pharmaceuticals, Inc. announced today that data from ENGAGE ... novel, oral small molecule inhibitor of class I histone ... with relapsed or refractory Hodgkin,s lymphoma (HL).  This data ... 8:00 PM PT at the American Society of ...
... Life Technologies Corporation today announced that its Ion Personal ... Innovative New Product "MIP" Awards luncheon hosted by CONNECT in ... disruptive technology in the gene sequencing field. Since ... uptake in research labs around the world and has been ...
Cached Biology Technology:Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 2Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... Scientists are reporting a new technique for mapping ... collected from the field and returned to a lab ... neither is readily available during a clean-up operation. The ... accurately predict the total amount of petroleum contaminants in ...
... bring forth the best properties of both ever since ... Age. In the latest successful merger, researchers at the ... of Maryland (UM) and the U.S. Food and Drug ... substances that individually have generated interest for their potential ...
... Cambridge, Md. (June 9, 2010) A team of scientists ... Point Laboratory will travel to the Gulf of Mexico later ... Horizon oil spill on plankton and fish communities in the ... Rapid Response Research (RAPID) grant for the expedition, which will ...
Cached Biology News:Predicting amount of oil in contaminated soils 2Liposome-hydrogel hybrids: No toil, no trouble for stronger bubbles 2